Loading clinical trials...
Loading clinical trials...
A Phase I, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LOXO-292 in Healthy Adult Subjects
Conditions
Interventions
Selpercatinib
Locations
1
United States
Celerion
Tempe, Arizona, United States
Start Date
February 12, 2019
Primary Completion Date
March 12, 2019
Completion Date
March 26, 2019
Last Updated
May 18, 2025
NCT06716502
NCT06290258
NCT00090662
NCT07310264
NCT07483606
NCT07310901
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions